Home » News » Drug Sponsors » Albemarle expands South Haven API production site

Albemarle expands South Haven API production site

Tuesday, July 10, 2012

Albemarle, a global developer, manufacturer and marketer of highly engineered specialty chemicals, has begun upgraded and expanded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Mich.

This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios.  In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status. 

Production using the new expanded capacity commenced on June 1, 2012. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!